KPTI

SEC source: 0001193125-25-205046 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,710

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-25-205044 · ownership.xml · nonDerivative · entry 2

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,390

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-25-205038 · ownership.xml · nonDerivative · entry 1

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,431

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

F2 · balance_after: Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

SEC source: 0001193125-25-205042 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,181

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

F2 · balance_after: Includes 922 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan on April 30, 2025.

SEC source: 0001193125-25-205049 · ownership.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,659

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

SEC source: 0001193125-25-205052 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,303

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

SEC source: 0001193125-25-205046 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,111

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

SEC source: 0001193125-25-205044 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,798

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

SEC source: 0002045943-25-000004 · ownership.xml · nonDerivative · entry 1

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,463

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-100373 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,223

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-097965 · ownership.xml · nonDerivative · entry 1

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,475

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-078944 · ownership.xml · derivative · entry 1

Greene Barry E · CIK 0001291963 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078961 · ownership.xml · derivative · entry 1

PAKIANATHAN DEEPIKA · CIK 0001270734 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078937 · ownership.xml · derivative · entry 1

BOHLIN GAREN G · CIK 0001254705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078938 · ownership.xml · derivative · entry 1

Schor Chen · CIK 0001340875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078974 · ownership.xml · derivative · entry 1

Su Zhen · CIK 0001991642 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078956 · ownership.xml · derivative · entry 1

Oliger Christy J. · CIK 0001822092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-078950 · ownership.xml · derivative · entry 1

Mirza Mansoor Raza · CIK 0001588389 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,600

Underlying: Common Stock · 4,600 shares

Expires 2035-05-27

F1 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · derivative.exercise_date: This option vests as to 100% of the underlying shares on May 28, 2026.

F1 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F1 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-065884 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,503

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-058137 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,853

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-051658 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,739

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.74 to $3.86, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034662 · ownership.xml · nonDerivative · entry 1

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,713

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034743 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,314

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 7, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.12 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034650 · ownership.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,047

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 16, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034736 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,984

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034732 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,272

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on April 4, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.11 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-034723 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,414

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.14 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-032305 · ownership.xml · derivative · entry 2

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,866

Underlying: Common Stock · 1,866 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032305 · ownership.xml · nonDerivative · entry 1

Abate Kristin · CIK 0002045943 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,284

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · derivative · entry 4

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,166

Underlying: Common Stock · 9,166 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F5 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · derivative · entry 3

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,833

Underlying: Common Stock · 10,833 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F5 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · nonDerivative · entry 2

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,759

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032323 · ownership.xml · nonDerivative · entry 1

Cheng Sohanya Roshan · CIK 0001865796 · EVP & Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,176

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · balance_after: Includes 824 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2022 Employee Stock Purchase Plan on October 31, 2024.

SEC source: 0000950170-25-032280 · ownership.xml · derivative · entry 4

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032280 · ownership.xml · derivative · entry 3

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,666

Underlying: Common Stock · 6,666 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032280 · ownership.xml · nonDerivative · entry 2

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,840

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032280 · ownership.xml · nonDerivative · entry 1

Mano Michael · CIK 0001837741 · SVP, General Counsel&Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,590

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032297 · ownership.xml · derivative · entry 2

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032297 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,678

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032315 · ownership.xml · derivative · entry 4

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,166

Underlying: Common Stock · 9,166 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032315 · ownership.xml · derivative · entry 3

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,833

Underlying: Common Stock · 10,833 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032315 · ownership.xml · nonDerivative · entry 2

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,859

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032315 · ownership.xml · nonDerivative · entry 1

Rangwala Reshma · CIK 0001825322 · EVP & Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,276

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · derivative · entry 4

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,166

Underlying: Common Stock · 9,166 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · derivative · entry 3

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,962

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,379

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-023192 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,714

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-014491 · ownership.xml · nonDerivative · entry 1

Paulson Richard A. · CIK 0001804460 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,120,158

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-012326 · ownership.xml · derivative · entry 2

Macomber Lori · CIK 0001968671 · EVP, CFO & Treasurer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-01-30

F2 · derivative.exercise_date: This option was granted on January 31, 2025 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on January 31, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.